Microarray analysis reveals that TP53- and ATM-mutant B-CLLs share a defect in activating proapoptotic responses after DNA damage but are distinguished by major differences in activating prosurvival responses

Tatjana Stanković(Cancer Research UK), Michael Hubank(Cancer Research UK), Debbie Cronin(Cancer Research UK), Grant S. Stewart(Cancer Research UK), Danielle Fletcher(Cancer Research UK), Colin R. Bignell(Cancer Research UK), Azra Alvi(Cancer Research UK), Belinda Austen(Cancer Research UK), Victoria Weston(Cancer Research UK), Chris Fegan(Cancer Research UK), Philip J. Byrd(Cancer Research UK), Paul Moss(Cancer Research UK), A. Malcolm R. Taylor(Cancer Research UK)
Blood
September 9, 2003
Cited by 99Open Access
Full Text

Abstract

The ATM/p53-dependent DNA damage response pathway plays an important role in the progression of lymphoid tumors. Inactivation of the ATM or TP53 gene is frequent in B-cell lymphocytic leukemia (B-CLL) and leads to aggressive disease. Although the ATM and p53 pathways overlap, they are not congruent, and it is unclear how the mechanism of tumor progression differs between ATM- and p53-deficient tumors. Using microarray analysis of ATM-mutant, TP53-mutant, and ATM/TP53 wild-type B-CLLs, we show that after exposure to DNA damage transcriptional responses are entirely dependent on ATM function. The p53 proapoptotic responses comprise only a part of ATM-regulated transcription; additionally, ATM regulates prosurvival responses independently of p53. Consequently, the greater severity of the TP53-mutant B-CLLs compared with ATM-mutant B-CLLs is consistent with the additive effect of defective apoptotic and elevated survival responses after DNA damage in these tumors. We also show that transcription expression profiles of ATM-deficient, TP53-deficient, and wild-type B-CLLs are indistinguishable before irradiation. Therefore, damage-induced transcriptional fingerprinting can be used to stratify tumors according to their biologic differences and simultaneously identify potential targets for treating refractory tumors.


Related Papers

No related papers found

Powered by citation graph analysis